Characteristics of All Patients Sent the ACQ and of Respondents and Nonrespondents
| Group | ||||
|---|---|---|---|---|
| Characteristic | Total (N = 434) | Nonrespondents (n = 101) | Respondents* (n = 333) | P Value |
| ACQ = Asthma Control Questionnaire.14,16 | ||||
| Note: Values are % (No.) unless indicated otherwise. | ||||
| * Primary and secondary respondents combined. | ||||
| † Calculated with the χ2 test. | ||||
| ‡ Calculated with the 1-way analysis of variance test. | ||||
| § Patients who visited their family physician for respiratory complaints, including visits for asthma exacerbations. | ||||
| || In the 2 years preceding the ACQ mailing. | ||||
| ¶ Calculated with the Mann-Whitney U test. | ||||
| # Receipt of at least 1 prescription for a bronchodilator or an inhaled steroid in the 2 years preceding the ACQ mailing. | ||||
| ** Proportion of inhaled steroid users; dosing groups are based on the Global Initiative for Asthma (GINA) classification.19 | ||||
| †† At least 1 exacerbation for which prednisolone or antibiotics were prescribed. | ||||
| Female | 58.5 (254) | 45.5 (46) | 62.5 (208) | .003† |
| Age, mean (SD), years | 34.1 (7.5) | 32.6 (7.5) | 34.6 (7.5) | .02‡ |
| Visitors§ | 47.7 (207) | 47.5 (48) | 47.7 (159) | .97† |
| Consultations, || mean (SD), No. | 1.1 (1.8) | 1.0 (1.6) | 1.2 (1.9) | .45¶ |
| Use of any asthma medication# | 75.3 (327) | 61.4 (62) | 79.6 (265) | <.001† |
| Use of inhaled steroid | 26.0 (113) | 16.8 (17) | 28.8 (96) | .02† |
| Low dose** | 8.5 (37) | 17.6 (3) | 35.8 (34) | – |
| Intermediate dose** | 9.4 (41) | 29.5 (5) | 37.9 (36) | .08† |
| High dose** | 7.8 (34) | 52.9 (9) | 26.4 (25) | – |
| Short-acting bronchodilator | 23.7 (103) | 19.8 (20) | 24.9 (83) | .29† |
| Long-acting β2 agonist | 6.0 (26) | 5.0 (5) | 6.3 (21) | .61† |
| Asthma exacerbation†† | 12.0 (52) | 8.9 (9) | 12.9 (43) | .28† |
| ACQ sum score, mean (SD) | – | – | 5.2 (5.2) | – |